571187-03-6

Basic information

• Product Name: 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE
• Synonyms: 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE;4-Methyl-N1-(4-(pyridin-3-yl)pyriMidin-2-yl)benzene-1,3-diaMine
• CAS NO: 571187-03-6
• Molecular Formula: C₁₆H₁₅N₅
• Molecular Weight: 277.32
• Mol File: 571187-03-6.mol

Chemical Properties

• Boiling Point: 542.773 °C at 760 mmHg
• Flash Point: 282.059 °C
• Appearance: /
• Density: 1.266 g/cm³
• Vapor Pressure: 7.65E-12mmHg at 25°C
• Refractive Index: 1.688
• CAS DataBase Reference: 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE(571187-03-6)
• EPA Substance Registry System: 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE(571187-03-6)

Safety Data

• Hazardous Substances Data: 571187-03-6(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
MK-2206 is used as an anticancer agent for the treatment of solid tumors with aberrant Akt signaling. It is particularly effective in targeting cancer cells that exhibit overactive Akt pathways, which are often associated with resistance to conventional therapies and poor prognosis.
Used in Combination Therapies:
MK-2206 is also being explored as a component of combination treatments to enhance the efficacy of existing cancer therapies. Its ability to inhibit the Akt pathway can potentially increase the sensitivity of cancer cells to other treatments, making it a valuable addition to multi-drug regimens.
Used in Pharmaceutical Research:
In the pharmaceutical industry, MK-2206 serves as a subject of ongoing research to further understand its therapeutic potential across various cancer types. This research aims to identify optimal dosing, administration methods, and patient populations that would benefit most from 6-METHYL-N'-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE.
Used in Drug Development:
MK-2206 is utilized in the development of new drugs targeting the Akt pathway, which is implicated in a range of diseases beyond cancer, including neurodegenerative disorders and cardiovascular diseases. Its role in drug development is to provide a foundation for creating more effective and targeted therapies.

InChI:InChI=1/C16H15N5/c1-11-4-5-13(9-14(11)17)20-16-19-8-6-15(21-16)12-3-2-7-18-10-12/h2-10H,17H2,1H3,(H,19,20,21)

Upstream product

• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 
• 99-55-8 2-methyl-5-nitroaniline 
• 350-03-8 methyl-3-pyridylketone 
• 796738-68-6 N₁-amino(imino)methyl-4-methyl-3-nitroaniline nitrate 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 796738-67-5 N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine 

Downstream Products

• 677704-35-7 4-diethylamino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-36-8 N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-pyrrolidinyl)-3-(trifluoromethyl)-benzamide 
• 677704-37-9 N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)-benzamide 
• 677704-38-0 N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(4-piperidinyl)-3-(trifluoromethyl)-benzamide 
• 677704-39-1 4-(4-methyl-1-piperazinyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-40-4 4-(1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-41-5 4-(2-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-42-6 4-(4-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-43-7 4-(2,4-dimethyl-1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide 
• 677704-44-8 3-(1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-5-(trifluoromethyl)-benzamide 
• 677704-45-9 3-(2-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-5-(trifluoromethyl)-benzamide 
• 677704-46-0 3-(4-methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide 
• 677704-47-1 N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)-benzamide 
• 677704-48-2 N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide 

Relevant articles and documents

Catalytic Activity of Nickel Nanoparticles in the Reaction of Reduction of Nitroarenes

Techniques for the production of nickel and nickel-cobalt nanoparticles and of their composites with polyvinylpyrrolidone were developed. The catalytic activity of the resulting compounds towards reduction of substituted nitroarenes was examined.

Facile synthesis of 2-phenylquinoline-4-carboxamide derivatives with variant structural features

The quinoline scaffold is an important class of heterocyclic compounds that possesses diverse chemotherapeutic activities. Thus, the 2-phenylquinoline-4- carboxamide derivatives containing a variety of moieties, such as 2-(2-furanyl)-1,3,4-oxadiazole, N-(2-methylphenyl)-4-(3-pyridinyl)-2- pyrimidinamine, 4,4′-bithiazole, purine, adamantine and resorcinol, have been designed and synthesized via Suzuki coupling, acid-base coupling and other typical reactions.

Functionally substituted Schiff bases in reduction reactions

Functionally substituted Schiff bases obtained by the condensation of nitroaniline, pyrimidinylaminoaniline, 5-aminoquinoline, 5-aminoquinaldine derivatives with 4-methylformylbenzoate were studied in the reactions of sodium borohydride with acidic activators, hydrazine hydrate in the presence of Raney nickel, Raney alloy in the presence of potassium hydroxide. By the reduction of azomethines new benzyl derivatives of aniline, quinolylamine, arylaminopyrimidine, and phenylenediamine were obtained.

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors

Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr-Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl and N-methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity.

N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-Phenyl-2-pyrimidine-aminine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or accute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer or cervical cancer, etc. of warm blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various disease, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.